Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors

For intraoperative imaging, antibodies labeled with both a radionuclide and a fluorophore may be used to tag the tumor lesion with a radiolabel and a fluorescent signal at high tumor to background ratios. However, labeling antibodies with fluorescent moieties may affect the in vivo behavior of the a...

Full description

Saved in:
Bibliographic Details
Main Authors: Mark Rijpkema, Desirée L. Bos, Alex S. Cornelissen, Gerben M. Franssen, David M. Goldenberg, Wim J. Oyen, Otto C. Boerman
Format: Article
Language:English
Published: SAGE Publishing 2015-07-01
Series:Molecular Imaging
Online Access:https://doi.org/10.2310/7290.2015.00015
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850088572234760192
author Mark Rijpkema
Desirée L. Bos
Alex S. Cornelissen
Gerben M. Franssen
David M. Goldenberg
Wim J. Oyen
Otto C. Boerman
author_facet Mark Rijpkema
Desirée L. Bos
Alex S. Cornelissen
Gerben M. Franssen
David M. Goldenberg
Wim J. Oyen
Otto C. Boerman
author_sort Mark Rijpkema
collection DOAJ
description For intraoperative imaging, antibodies labeled with both a radionuclide and a fluorophore may be used to tag the tumor lesion with a radiolabel and a fluorescent signal at high tumor to background ratios. However, labeling antibodies with fluorescent moieties may affect the in vivo behavior of the antibody depending on the dye to antibody substitution ratio. To investigate the optimal substitution ratio for use in dual-modality image-guided surgery, we conjugated three different antibodies, MN-14 (anti-CEACAM5), girentuximab (anti-CAIX), and cetuximab (anti-EGFR), with both diethylene triamine pentaacetic acid (DTPA, for labeling with 111 In) and IRdye 800CW at dye to antibody ratios of 0, 1, 1.5, 2, and 3 and assessed in vivo behavior. Biodistribution studies showed that at high dye to antibody ratios, liver uptake of the dual-labeled antibodies increased, whereas tumor uptake decreased. Conversely, very low ratios may not be optimal either because in that case, only a few antibody molecules will be dual-labeled (i.e., contain both a DTPA and an IRDye 800CW moiety), which may complicate interpretation of dual-modality data. The present study shows that, provided that the chelator to antibody ratio is high enough, a dye to antibody ratio in the range of 1 to 1.5 is optimal for antibody-targeted dual-modality imaging applications. However, the optimal configuration is antibody dependent and should be determined for each dual-labeled antibody individually.
format Article
id doaj-art-31b0e1408a76493db72a0bc7b545300a
institution DOAJ
issn 1536-0121
language English
publishDate 2015-07-01
publisher SAGE Publishing
record_format Article
series Molecular Imaging
spelling doaj-art-31b0e1408a76493db72a0bc7b545300a2025-08-20T02:42:59ZengSAGE PublishingMolecular Imaging1536-01212015-07-011410.2310/7290.2015.0001510.2310_7290.2015.00015Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of TumorsMark RijpkemaDesirée L. BosAlex S. CornelissenGerben M. FranssenDavid M. GoldenbergWim J. OyenOtto C. BoermanFor intraoperative imaging, antibodies labeled with both a radionuclide and a fluorophore may be used to tag the tumor lesion with a radiolabel and a fluorescent signal at high tumor to background ratios. However, labeling antibodies with fluorescent moieties may affect the in vivo behavior of the antibody depending on the dye to antibody substitution ratio. To investigate the optimal substitution ratio for use in dual-modality image-guided surgery, we conjugated three different antibodies, MN-14 (anti-CEACAM5), girentuximab (anti-CAIX), and cetuximab (anti-EGFR), with both diethylene triamine pentaacetic acid (DTPA, for labeling with 111 In) and IRdye 800CW at dye to antibody ratios of 0, 1, 1.5, 2, and 3 and assessed in vivo behavior. Biodistribution studies showed that at high dye to antibody ratios, liver uptake of the dual-labeled antibodies increased, whereas tumor uptake decreased. Conversely, very low ratios may not be optimal either because in that case, only a few antibody molecules will be dual-labeled (i.e., contain both a DTPA and an IRDye 800CW moiety), which may complicate interpretation of dual-modality data. The present study shows that, provided that the chelator to antibody ratio is high enough, a dye to antibody ratio in the range of 1 to 1.5 is optimal for antibody-targeted dual-modality imaging applications. However, the optimal configuration is antibody dependent and should be determined for each dual-labeled antibody individually.https://doi.org/10.2310/7290.2015.00015
spellingShingle Mark Rijpkema
Desirée L. Bos
Alex S. Cornelissen
Gerben M. Franssen
David M. Goldenberg
Wim J. Oyen
Otto C. Boerman
Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors
Molecular Imaging
title Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors
title_full Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors
title_fullStr Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors
title_full_unstemmed Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors
title_short Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors
title_sort optimization of dual labeled antibodies for targeted intraoperative imaging of tumors
url https://doi.org/10.2310/7290.2015.00015
work_keys_str_mv AT markrijpkema optimizationofduallabeledantibodiesfortargetedintraoperativeimagingoftumors
AT desireelbos optimizationofduallabeledantibodiesfortargetedintraoperativeimagingoftumors
AT alexscornelissen optimizationofduallabeledantibodiesfortargetedintraoperativeimagingoftumors
AT gerbenmfranssen optimizationofduallabeledantibodiesfortargetedintraoperativeimagingoftumors
AT davidmgoldenberg optimizationofduallabeledantibodiesfortargetedintraoperativeimagingoftumors
AT wimjoyen optimizationofduallabeledantibodiesfortargetedintraoperativeimagingoftumors
AT ottocboerman optimizationofduallabeledantibodiesfortargetedintraoperativeimagingoftumors